PMID- 30685073
OWN - NLM
STAT- MEDLINE
DCOM- 20190502
LR  - 20190502
IS  - 1532-8708 (Electronic)
IS  - 0093-7754 (Linking)
VI  - 46
IP  - 1
DP  - 2019 Feb
TI  - Managing the adverse events associated with lenvatinib therapy in 
      radioiodine-refractory differentiated thyroid cancer.
PG  - 57-64
LID - S0093-7754(18)30220-3 [pii]
LID - 10.1053/j.seminoncol.2018.11.004 [doi]
AB  - Lenvatinib is a multikinase inhibitor of vascular endothelial growth factor 
      (VEGF) receptors 1-3, fibroblast growth factor receptors 1-4, RET, KIT, and 
      platelet-derived growth factor receptor-alpha. Lenvatinib is approved as a 
      monotherapy for the treatment of radioiodine-refractory differentiated thyroid 
      cancer and in combination with everolimus for the second-line treatment of 
      advanced renal cell carcinoma. Lenvatinib is also under investigation for the 
      treatment of several malignancies including unresectable hepatocellular 
      carcinoma. Although lenvatinib is associated with favorable efficacy, it is 
      associated with adverse events (AEs) that the clinician will have to closely 
      monitor for and proactively manage. Most of these AEs are known class effects of 
      VEGF-targeted therapies, including hypertension, diarrhea, fatigue or asthenia, 
      decreased appetite, and weight loss. This review summarizes the safety profile of 
      lenvatinib and offers guidance for the management of both frequent and rare AEs. 
      We discuss the potential mechanisms underlying these AEs and present practical 
      recommendations for managing toxicities. The development of treatment plans that 
      include prophylactic and therapeutic strategies for the management of 
      lenvatinib-associated AEs has the potential to improve patient quality of life, 
      optimize adherence, minimize the need for dose reductions, treatment 
      interruptions, or discontinuations, and maximize patient outcomes.
CI  - Copyright (c) 2018 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Cabanillas, Maria E
AU  - Cabanillas ME
AD  - Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas 
      MD Anderson Cancer Center, Houston, TX, USA. Electronic address: 
      mcabani@mdanderson.org.
FAU - Takahashi, Shunji
AU  - Takahashi S
AD  - Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation 
      for Cancer Research, Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20181221
PL  - United States
TA  - Semin Oncol
JT  - Seminars in oncology
JID - 0420432
RN  - 0 (Iodine Radioisotopes)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinolines)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EE083865G2 (lenvatinib)
SB  - IM
MH  - Carcinoma, Hepatocellular/drug therapy/epidemiology/pathology
MH  - Carcinoma, Renal Cell/drug therapy/epidemiology/pathology
MH  - Drug-Related Side Effects and Adverse Reactions/*epidemiology/pathology
MH  - Everolimus/adverse effects/therapeutic use
MH  - Humans
MH  - Iodine Radioisotopes/*therapeutic use
MH  - Liver Neoplasms/drug therapy/epidemiology/pathology
MH  - Phenylurea Compounds/*adverse effects/therapeutic use
MH  - Protein Kinase Inhibitors/adverse effects/therapeutic use
MH  - Quinolines/*adverse effects/therapeutic use
MH  - Thyroid Neoplasms/*drug therapy/epidemiology
OTO - NOTNLM
OT  - Adverse event
OT  - Differentiated thyroid cancer
OT  - Lenvatinib
OT  - Side effect
OT  - Tyrosine kinase inhibitor
EDAT- 2019/01/28 06:00
MHDA- 2019/05/03 06:00
CRDT- 2019/01/28 06:00
PHST- 2018/11/02 00:00 [received]
PHST- 2018/11/21 00:00 [accepted]
PHST- 2019/01/28 06:00 [pubmed]
PHST- 2019/05/03 06:00 [medline]
PHST- 2019/01/28 06:00 [entrez]
AID - S0093-7754(18)30220-3 [pii]
AID - 10.1053/j.seminoncol.2018.11.004 [doi]
PST - ppublish
SO  - Semin Oncol. 2019 Feb;46(1):57-64. doi: 10.1053/j.seminoncol.2018.11.004. Epub 
      2018 Dec 21.